Aptose Biosciences Inc.
APTOF$22M
Micro CapNASDAQBiological Products, (No Diagnostic Substances)🇺🇸North AmericaTORONTO13 employees
Drugs in Pipeline
3
Phase 3 Programs
1
Upcoming Catalysts
1
Next Catalyst
Nov 2026
Market Overview
Stock performance and key metrics
APTOF News
Catalyst Timeline
1 upcoming, 0 past
Drug Pipeline
Virulizin®
Pancreatic Cancer
GTI-2040
Acute Myeloid Leukemia
Tuspetinib
Leukemia, Myeloid, Acute
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Virulizin® | Phase 3 | Pancreatic Cancer | - | - |
GTI-2040 | Phase 2 | Acute Myeloid Leukemia | - | - |
Tuspetinib | Phase 2 | Leukemia, Myeloid, Acute | - | - |
Pancreatic Cancer
1 drug in this indication
Acute Myeloid Leukemia
1 drug in this indication
Leukemia, Myeloid, Acute
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Catalyst Verdict
Market-Implied Move
Regulatory Approvals
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply